Multidisciplinary Discussion and Management of Rectal Cancer: A Population-based Study by Swellengrebel, H. A. M. et al.
Multidisciplinary Discussion and Management of Rectal Cancer:
A Population-based Study
H. A. M. Swellengrebel • E. G. Peters • A. Cats • O. Visser •
H. G. T. Blaauwgeers • V. J. Verwaal • M. L. van Velthuysen •
H. A. Cense • S. C. Bruin • C. A. M. Marijnen
Published online: 1 July 2011
 The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract
Background The purpose of the present study was to
evaluate the value of discussing rectal cancer patients in a
multidisciplinary team (MDT).
Methods All treated rectal cancer patients ([T1M0)
diagnosed in 2006–2008 were included. According to the
national guidelines, neoadjuvant (chemo)radiotherapy
should be given to all rectal cancer patients. Patients were
scored as ‘‘discussed’’ (MDT?) only if documented proof
was available. The primary endpoint was the number of
positive circumferential resection margins (CRM B1 mm).
Results Of the 275 patients included, 210 were analyzed
(exclusions: (recto)sigmoid tumor, acute laparotomy, and
inoperability). Neoadjuvant treatment was applied in 174
(83%) patients and followed by total mesorectal excision in
171 (81%) patients. Patients considered not to require
downstaging, received short-course radiotherapy (SCRT)
(n = 116) or no radiotherapy (no RT) (n = 36), whereas
58 more advanced patients received chemoradiotherapy
(CRT). The MDT discussion took place in 116 cases
(55%). In the MDT? group an MRI was used more often
(p = 0.001) and TNM staging was more complete
(p\0.001). The proportion of patients with advanced
disease was higher in the MDT? group (88% CT3/N?
versus 68%; p = 0.001). The overall CRM? rate was 13%
and did not differ between the MDT? and the MDT-
group (p = 0.392). In patients receiving SCRT or no RT,
the CRM? rate was 10%, whereas the rate was 20% for
patients receiving CRT.
Conclusions Although no difference in CRM? rate was
found for those patients who were discussed and those who
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DOI 10.1007/s00268-011-1181-9were not, our results demonstrate room for improvement,
especially in the selection of patients for SCRT or no RT.
We advocate standardized documentation of treatment
decisions and pathology reports.
Introduction
Over the last 10–15 years, the treatment of rectal cancer
has evolved tremendously. Results of randomized con-
trolled trials [1–3] have led to the introduction of ‘‘total
mesorectal excision’’ (TME) [4] and preoperative
(chemo)radiotherapy in Western Europe. Further research
has established the role of the pathologist and radiologist in
optimizing the multidisciplinary treatment of rectal cancer.
Identiﬁcation of tumor B1 mm from the circumferential
resection margin (CRM?) has proved to be a strong pre-
dictor of local recurrence, distant metastases, and survival,
resulting in a new surrogate endpoint of rectal cancer
treatment [5–8]. Meanwhile, two radiological studies [9,
10] demonstrated that MRI can accurately predict
involvement of this surgical CRM, thereby shifting the
importance of an accurate T-stage on MRI to the more
clinically appealing mesorectal fascia (MRF) at risk for a
positive CRM after TME.
With regard to daily practice, the multimodality char-
acter and different treatment approaches have made the
treatment of rectal cancer complex for health care profes-
sionals. An optimal patient-tailored decision-making pro-
cess requires adequate interdisciplinary communication
and coordination. Burton et al. have shown that a MRI
directed multidisciplinary team (MDT) discussion of rectal
cancer patients with implementation of a preoperative
stratiﬁcation signiﬁcantly reduced the CRM? rate [11]. In
certain patient groups, MDT discussion is increasingly
becoming part of the standard of care, but evidence of its
direct effect on the quality of cancer care remains limited
[12]. Rectal cancer treatment guidelines for the Nether-
lands were introduced in 2004 and recommend that all
patients be discussed by a MDT, irrespective of tumor
stage or treatment plan. At the MDT meeting, patients are
stratiﬁed according to risk of a positive CRM and sub-
sequent local recurrence, and treated accordingly. Possible
beneﬁts of a more standardized approach to preoperative
and histopathological staging are that certain parameters
for quality assurance and possibilities for direct feedback to
the MDT arise. For instance, patients receiving short-
course radiotherapy (SCRT) or TME only should all have a
negative CRM after TME, as otherwise chemoradiotherapy
(CRT) would have been the preferred preoperative treat-
ment to induce preoperative downstaging.
We studied surgical outcome after the introduction of
TME with the administration of (chemo)radiotherapy in
selected cases of rectal cancer in the greater Amsterdam
region. The aim of this population-based study was to
evaluate the additional value of discussing rectal cancer
patients in a MDT, with the occurrence of a positive CRM
as endpoint. Additional aims were to audit preoperative and
histopathological staging and the implementation of pre-
operative risk stratiﬁcation according to national
guidelines.
Patients and methods
Patients
All patients diagnosed with cT2–4, N0–2 rectal cancer
(TNM, 5th edition [13]) in one of six referring hospitals
and one cancer referral center in the greater Amsterdam
region, between January 2006 and January 2008, were
included in the study. Exclusion criteria included patients
with low risk cancer (cT1N0) who underwent local exci-
sion only, previous invasive cancers, a tumor located above
the peritoneal deﬂection or more than 15 cm from the anal
verge, or patients with metastasized disease.
Data collection
The Comprehensive Cancer Centre Amsterdam (CCCA) is
an independent regional, population-based cancer registry
with complete coverage of a population of approximately 3
million inhabitants. Following histopathological diagnosis,
cancer patients are identiﬁed from the nationwide pathol-
ogy registry (PALGA) and prospectively entered into the
registry. This pathology registry also assures complete
coverage of all patients diagnosed in the region, enabling a
true population based study. Registration clerks routinely
extract data on tumor stage, treatment, and follow-up from
hospital and outpatient records. Additional information, not
routinely collected, was collected retrospectively by the
registration clerks of the CCCA or by one of the authors
(either H.A.M.S. or E.G.P.) and included type of imaging
for preoperative staging, discussion by a MDT, treatment
decisions, and treatment outcome.
MDT
In the regional referral network of the cancer institute,
patients are discussed in a multidisciplinary oncology
meeting at the referring hospital. During an MDT discus-
sion patient history, clinical and psychological condition,
co-morbidity, modes of work-up, clinical staging, and
optimal treatment strategies are discussed. The multidis-
ciplinary team members present include a consulting on-
cologic surgeon, a radiation oncologist, and a medical
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123oncologist (all from the cancer institute); the treating spe-
cialists (surgical oncologist, medical oncologist); and a
radiologist, a pathologist, and a specialized nurse (nurse
practitioner or case manager). If the MDT at the referring
hospital decides to treat the patient with neoadjuvant
radiotherapy, the patient is referred to the cancer institute.
In case of doubt, when the optimal treatment approach is
queried by the radiation oncologist at the cancer institute,
or when a locally advanced tumor is suspected, the patient
is also discussed in the cancer institute’s specialized gas-
trointestinal cancer MDT.
Patients were scored as ‘‘discussed’’ (MDT?) only if
documented proof was available that the patient had been
discussed preoperatively at a MDT meeting, either in a
referring institution or in the cancer institute.
Treatment
In the Netherlands, patients are stratiﬁed into three risk
groups, each with a different treatment approach based on
the risk of a positive CRM and subsequent local recurrence.
Low-risk patients, deﬁned as those with superﬁcial tumors
(T1N0) where treatment with local excision sufﬁces, were
excluded from the study. The intermediate risk group
consists of patients with mobile resectable tumors (T2 and
small T3, N0–1), suitable for treatment with preoperative
5 9 5 Gy radiotherapy (short-course radiotherapy; SCRT)
followed directly by TME. In patients with small proximal
tumors without clinical node metastasis, where the addi-
tional value of radiotherapy is under debate, preoperative
SCRT may be withheld after discussion in a MDT. The
high-risk group includes patients with locally advanced
tumors, where the MRF and consequent surgical CRM is
threatened or involved, or where extensive lymph node
involvement is expected. In this group, the treatment of
choice consists of preoperative downstaging with long-
course radiotherapy (25 9 2 Gy) in combination with ﬂu-
oropyrimidine-based chemotherapy [3, 14–16], followed
by TME 6–8 weeks later. Standard chemotherapy in the
study period was capecitabine, 825 mg/m
2 twice daily on
days 1–33. In three patients, bevacizumab (5 mg/kg IV on
days -14, 1, 15, and 29) was added in trial setting. Four
patients received 50 Gy only because chemotherapy was
contraindicated.
Pathology
An involved CRM (CRM?) was deﬁned as tumor or an
involved lymph node B1 mm from the CRM. If the CRM
was not mentioned in the report (n = 81), additional
investigation of the CRM was performed by a pathologist
(M.L.V.).
Statistical analysis
Data were entered into a database and analyzed with the
Statistical Package for the Social Sciences (version 15.0 for
Windows; SPSS, Chicago, IL). To determine signiﬁcance
in differences between groups of patients, chi-square tests
were used for categorical variables unless stated otherwise,
whereas the t-test and the Mann–Whitney U-test were used
for continuous variables. A p value of \0.05 (two-sided)
was regarded statistically signiﬁcant.
Results
Initially, 275 patients with intermediate or high-risk rectal
cancer were identiﬁed. Patients whose tumors were inop-
erable (n = 24), patients undergoing non-elective surgery
(n = 1), and those with a (recto)sigmoid tumor (n = 40)
were excluded, leaving 210 patients suitable for analysis.
Fifty-ﬁve percent (116/210) of all patients were discussed
by a MDT. In Table 1, baseline patient and treatment
characteristics are shown for all patients, and also for
MDT? and MDT- groups. Of the discussed patients, 50%
were discussed at the referring hospital only, 20% were
discussed both at the referring hospital and at the cancer
institute, and 30% were discussed at the cancer institute
only.
Staging
Of the 210 patients, 178 (85%) had a clinical TNM stage
reported, including both a T stage and an N stage. In the
MDT? group, staging was more complete (94% versus
73%; p\0.001), and a MRI study was also performed
more often (p = 0.001). In addition, the proportion of
patients with advanced disease (CT3 and/or N?) was
higher (p = 0.001) in the MDT? group. Correlation of the
clinical and pathological T and N stages of the subgroup of
patients receiving SCRT or TME only (to exclude down-
staging effects of CRT) revealed a staging accuracy for T
stage of 57% (Table 2) and N stage of 63%. In Table 2
only patients with complete cT and pT are included. No
signiﬁcant difference in tumor or nodal staging accuracy
(understaging, accurate, overstaging) was found between
the MDT? and MDT- groups (p = 0.139 and 0.902).
Treatment
Preoperative (chemo)radiotherapy was employed in 174
(83%) patients. Three patients did not proceed to surgery
due to death during CRT, poor performance status, and
local progression, respectively. Thirty-six patients under-
went TME only. Patients receiving preoperative
World J Surg (2011) 35:2125–2133 2127
123Table 1 Patient and treatment
characteristics according to
discussion by a MDT
SCRT short course radiotherapy,
CRT chemoradiotherapy, LAR
low anterior resection, APR
abdominoperineal resection, Pt
patients
a Percentages are column
percentages unless stated
otherwise and are rounded off
b Percentage is of the total
number of patients
c Binomial test
d Linear-by-linear association
e (Chemo)radiotherapy versus
no radiotherapy
f APR versus sphincter sparing
surgery
Total MDT? MDT- p value
Number %
a Number %
a Number %
a
Total patients 210 100 116 55
b 94 45
b 0.147
c
Sex
Male 122 58 63 54 59 63 0.217
Female 88 42 53 46 35 37
Age
Median 70 69 70 0.312
Range 37–89 37–87 41–89
Tumor location
0–5 cm 75 36 52 45 23 24 0.002
6–10 89 42 46 40 43 46
[10 45 21 17 15 28 30
Unknown 1 1 1 1 0 0
MRI
Yes 175 83 106 91 69 73 0.001
No 35 17 10 9 25 27
Clinical tumor stage (cT)
1 6 3 2 2 4 4 0.001
d
2 4 7 2 22 0 1 72 7 2 9
3 103 49 67 58 36 38
4 3 0 1 42 5 2 25 5
Unknown 24 11 2 2 22 23
Clinical node stage (cN)
0 108 51 55 47 53 56 0.014
d
1 6 9 3 34 0 3 42 9 3 1
2 17 8 15 13 2 2
Unknown 16 8 6 5 10 11
Advanced stage (CT3 or N?) n = 198
Yes 149 81 99 88 50 68 0.001
No 36 20 13 12 23 32
Type of preoperative treatment
None 36 17 7 6 29 31 \0.001
e
SCRT 116 55 61 53 55 59
CRT 58 27 48 41 10 11
Type of surgery
LAR 115 55 48 41 67 71 \0.001
f
Hartmann 28 13 20 17 8 9
APR 64 31 46 40 18 19
No surgery 3 1 2 2 1 1
Histopathological tumor stage (pT) n = 207
0 9 4 8 7 1 1 0.262
d
1 2 0 1 01 1 1 09 1 0
2 6 8 3 23 5 3 13 3 3 5
3 102 49 56 49 46 49
48 4 4 4 4 4
Histopathological nodal stage (pN) n = 207
0 130 63 73 64 57 61 0.437
b
1 5 0 2 42 6 2 32 4 2 6
2 2 6 1 31 5 1 31 1 1 2
Unknown 1 0 0 0 1 1
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123(chemo)radiotherapy were discussed more often by a MDT
than those undergoing TME only (63% versus 19%;
p\0.001). Furthermore, patients with distal tumors
(B5 cm from the anal verge) were more likely to be dis-
cussed in a MDT than those with more proximal (6–15 cm)
tumors (69% versus 47% MDT?; p = 0.002).
Outcome
The CRM was initially reported in 126 (61%) and addi-
tionally measured in 71 (34%) of the 207 resected patients,
whereas in 10 patients the CRM remained unknown. In
total, in 24 patients a positive CRM was documented after
resection, while in one patient the tumor was irresectable
after CRT, resulting in an overall CRM? rate of 13% (25/
198). An APR was not associated with signiﬁcantly more
CRM? resections (18% versus 10% after sphincter-saving
resections; p = 0.093). Increasing pathological T- and
N-stage were both associated with increasing CRM? rates
(p B 0.001 and p = 0.001, respectively).
The ﬂow diagram in Fig. 1 illustrates outcome after
different treatment strategies. The CRM? rate for inter-
mediate risk patients (i.e., those receiving SCRT or no RT)
was 10% (14/143) while it was 20% (11/55) after CRT
(including one irresectable patient). Furthermore, in the
intermediate risk subgroup, distal tumors were associated
with more CRM? resections (8/38 CRM?; p = 0.011)
compared to those located 6–15 cm from the anal verge (6/
105 CRM?).
Table 3 shows CRM involvement according to MDT
discussion. The overall CRM? rate did not differ signiﬁ-
cantly between the MDT? group (14%, 16/111) and the
MDT- group (10%, 9/87) (p = 0.392), even when patients
with a positive CRM determined by an involved node were
excluded from the comparison (p = 0.198). When ana-
lyzing the subgroup of intermediate risk patients (receiving
SCRT or no RT) only, the CRM? rate remained similar
(12% versus 8%, respectively; p = 0.385). The root-cause
analysis in Table 4 describes the characteristics and
Table 2 Correlation of the clinical and pathological T stages of the
subgroup of patients not receiving CRT
pT Total
c T 1234
1 3 30 0 6
21 0 22 10 1 43
33 2 2 45 27 2
40 1 2 1 4
Total 16 48 57 4 125
210 rectal cancer patients
No RT
n=36
CRT
N=58
SCRT
N=116
No Surgery
n=3
TME
n=55
TME
n=116
CRM+
n=12 (11%) 
TME
n=36
CRM+
n=2 (6%)
CRM-
n=30 (94%)
CRM  uk
n=4
CRM -
n=99 (89%)
CRM  uk
n= 5
CRM+
n=11 (20%)
CRM -
n=44 (80%)
CRM  uk
n= 1
Overall CRM+ = 13% (25/198)
1 irresectable
patient
Fig. 1 Flow diagram of
treatment and CRM? rate
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123treatment of those patients with a CRM? outcome after
TME only or SCRT. Of these 14 patients with a positive
CRM not treated with CRT, discussion in a MDT could not
have prevented the positive CRM in 8 patients, while the
other 6 patients were not discussed by a MDT. Strikingly,
among non-discussed patients with a positive CRM, 3
patients had a pathological T4 tumor that was not recog-
nized during preoperative staging.
Table 3 CRM involvement according to MDT discussion
MDT? (%) (n = 114) MDT- (%) (n = 94) Total
Preoperative
treatment
CRM
[1m m
Primary tumor
B1m m
Positive node
B1m m
uk CRM
[1m m
Primary tumor
B1m m
Positive node
B1m m
uk
None 6 (100) 0 0 1 24 (92) 1 (4) 1 (4) 3 36
SCRT 52 (87) 7 (12) 1 (2) 1 47 (92) 3 (6) 1 (2) 4 116
CRT 37 (82) 7 (16) 1 (2) 1 7 (70) 2
a (20) 1 (10) 0 56
Total 95 (86) 14 (13) 2 (2) 3 78 (90) 6 (7) 3 (3) 7 208
a
MDT? discussed by a multidisciplinary team, MDT- not discussed, CRM circumferential resection margin, CRT chemoradiotherapy, SCRT
short-course radiotherapy, uk unknown
a Including 1 irresectable tumor
Table 4 CRM-positive
patients: a root-cause analysis
No information on the
completeness of the surgical
specimen was available
MDT multidisciplinary team
Patient
number
Height of
tumor, cm
MDT?/-
and
location
MRI Preoperative
therapy
Operative
procedure
CRM,
mm
Tumour or
node at
CRM
TN
stage
1 0–5 – No None Hartmann 0 Tumor cT4Nx
pT4N0
2 0–5 – Yes SCRT LAR 0 Lymph node cT3N1
pT3N1
3 0–5 – Yes SCRT LAR B1 Tumor cT3N1
pT3N0
4 0–5 Referring
hospital
Yes SCRT Hartmann £1 Tumor cT3N0
pT3N2
5 0–5 Referring
hospital
Yes SCRT APR £1 Tumor cT2N0
pT3N0
6 0–5 Referring
hospital
Yes SCRT APR £1 Tumor cT2N1
pT2N0
7 0–5 Referring
hospital
Yes SCRT APR 0 Tumor cT3N1
pT2N2
8 0–5 Cancer
Institute
Yes SCRT APR B1 Lymph node cT2N2
pT2N2
9 6–10 – Yes SCRT LAR 0 Tumor cT2N0
pT4N2
10 6–10 – Yes SCRT APR 0 Tumor cT3N1
pT4N0
11 6–10 Referring
hospital
Yes SCRT LAR 0 Tumor cT3N1
pT3N1
12 6–10 Both Yes SCRT LAR 0 Tumor cT3N0
pT3N1
13 [10 – No None LAR B1 Lymph node cTxN0
pT3N1
14 [10 Cancer
Institute
Yes SCRT Hartmann B1 Tumor cT3N0
pT3N1
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123Discussion
This population-based study represents daily practice in the
Netherlands in the era following the TME trial. Only half
of the patients diagnosed with rectal cancer in our region
are discussed by a MDT. As predominantly advanced
patients were selected for discussion, this may have inﬂu-
enced the study outcome whereby no signiﬁcant beneﬁt
was found for MDT discussion on the CRM? rate. We
found an overall CRM? rate of 13%, while for the sub-
group of patients in which preoperative downstaging was
not deemed necessary, the rate was 10%. Documenting the
CRM in the pathology report has not yet become a feature
of the standard of care, as initially it was documented in
only 61% of patients.
CRM? rates in the literature
In the TME trial, patients with resectable rectal cancer
were randomized between TME alone and SCRT followed
by TME within 10 days. In this quality-controlled study
undertaken in the era preceding the use of MRI, the
reported CRM? rates after macroscopic complete resec-
tion were 18% and 16%, respectively [17]. The CRM rate
of 10% in patients receiving SCRT or TME only in our
study reﬂects progression in this ﬁeld; but it also illustrates
room for further improvement in patient selection, espe-
cially in patients receiving SCRT (11% CRM?). In the
MRC CR07 study, a study comparable to the TME trial, the
CRM? rates were 10% of those undergoing a macroscopic
complete resection in the SCRT arm and 12% in the TME
alone arm [2]. During this study period the MRI was being
introduced as selection tool, with 41% of patients staged
with MRI, indicating the advantages of MRI in patient
selection.
Effect of the MDT discussion
Dutch rectal cancer treatment guidelines recommend dis-
cussing all patients in a MDT meeting. As mentioned
above, our study shows that this is not yet the case in our
region.
Despite the fact that recording the results of the MDT
discussion is mandatory in the Netherlands, it is possible
that we underestimated the number of patients discussed
because there was a lack of documentation. The use of a
pro forma for all patients would facilitate more complete
documentation of the discussion or the reason why a
patient was not discussed. Burton et al. [11] evaluated the
effects of regional implementation of a MDT discussion
and reported a CRM? rate of 13%, which is equal to ours.
In contrast to our study, they showed that discussion by a
MDT was associated with a signiﬁcantly lower CRM? rate
(26% versus 8%). At re-audit one year later, after intro-
duction of compulsory MDT discussion for all rectal can-
cer patients, 96% were discussed and the CRM? rate was
decreased to 7% overall, which emphasizes the importance
and effect of multidisciplinary interaction in their region.
Due to a selection of advanced patients for discussion a
true comparison between MDT? and MDT- patients in
our series is difﬁcult, especially because advanced patients
have a higher a priori risk of a CRM? resection, thereby
undermining the value of the MDT. Although acceptable
CRM? rates were obtained with this selective discussion
approach, there is room for improvement. In fact, six
CRM? patients, who were not discussed and received
SCRT or no RT, might have beneﬁtted from a discussion
by a MDT. This is underscored by the fact that three of
these patients had a pT4 tumor, indicating that CRT was
absolutely necessary. We therefore advocate discussion of
all rectal cancer patients in a MDT.
Regarding the MDT itself, eight patients discussed in a
MDT received SCRT but ended up with a positive CRM,
indicating that the MDT itself also needs improvement.
However, another confounding factor may be the quality of
the surgical specimen (Table 4).
Pre-treatment staging
With regard to preoperative staging, T-staging accuracy
with MRI was 57%, similar to that of the MERCURY
group in their national MRI implementation program
(53%) [18]. Inaccuracy in distinguishing T1 from a T2
(34% in our study) and T2 from a T3 (32%) reported in this
study is in line with the literature and indicates that MRI
does have its limits in T and N staging [9]. However, recent
studies [9, 10] have shown that a shift in staging has taken
place from primarily an accurate T-stage on MRI to a more
clinically important mesorectal fascia (MRF) at risk for a
positive CRM after TME. In our study, treatment stratiﬁ-
cation was based on the risk of a positive CRM (\2m ma t
risk), but exact distances to the MRF on MRI were not
documented. Twelve of the 14 patients with a positive
CRM after SCRT or TME only were staged with MRI,
indicating that more attention is needed to accurately select
patients at risk. A pro forma with standardized quantiﬁ-
cation of margins, tumor inﬁltration depth, and size and
aspects of nodes might facilitate further optimization of
staging. Furthermore, a MRI-based MDT discussion will
lead to a better understanding of the anatomy of the rectal
tumor, which is important for all specialists involved.
Post-chemoradiotherapy re-staging
In the 11 patients with a positive resection margin after
CRT, a complete resection was not possible, indicating that
World J Surg (2011) 35:2125–2133 2131
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always achieved. Re-staging after chemoradiotherapy,
which was not the standard of care during this study period,
might have optimized treatment by enabling the surgeon to
plan the resection according to the (lack of) response or to
even to decide to delay surgery to optimize response.
However, on MRI microscopic tumor deposits remain
difﬁcult to distinguish from a benign desmoplastic reaction.
Possibly, positron emission tomographic (PET) scanning
would aid the identiﬁcation of vital and metabolically
active tumor cells. Other possibilities to further decrease
the CRM? rate after CRT include centralization of the
treatment and further optimization of the synergistic effect
of chemoradiotherapy on tumor downstaging with either
intensiﬁed chemoradiotherapy or tumor-speciﬁc biologi-
cals, like vascular endothelial growth factor (VEGF)
inhibitors. However, whether this approach will really lead
to better clinical outcome remains to be seen. In the
ACCORD 12 trial [19], T3–4M0 rectal cancer patients
were randomized between 45 Gy RT with capecitabine or
50 Gy RT with capecitabine and oxaliplatin. A signiﬁcant
decrease in CRM? resections with intensiﬁed CRT (19%
versus 10%; p = 0.02) was observed. Whether this was
due to the increased radiotherapy dose or the addition of
oxaliplatin remains speculative.
Study limitations
Because of the retrospective population-based nature of
this study; some limitations need to be addressed. We only
scored patients as MDT? if documented proof was avail-
able that the patient had been discussed preoperatively at a
MDT meeting. It is possible that the number of patients
discussed by a MDT has been underreported. Exact details
on treatment decisions and reasons underlying them—for
instance: patient unﬁt for chemo(radiotherapy)—were not
available. Regarding patient outcome, follow-up was not
long enough to demonstrate the prognostic importance of a
positive CRM with regard to the (local) recurrence rate or
overall survival.
Conclusions
In conclusion, in our region MRI-based preoperative
stratiﬁcation has led to a selective approach to MDT, with
55% of patients being discussed. Even though national
guidelines state that all patients should be discussed in a
MDT before treatment is begun, this is not yet the case in
clinical practice. Interestingly, even though the group of
patients discussed consisted of those with higher risk for a
positive CRM because of their advanced stage of disease,
this did not result in more CRM positivity in comparison to
the group of patients not discussed by a MDT, most of
whom had less advanced disease. In this latter group one
would expect fewer positive CRM resections. The CRM?
rate of 10% in patients not receiving CRT indicates room
for improvement. The message of this study is clear: the
implementation of MRI in optimizing patient selection has
not yet reached its full potential. Standardized staging
(MRI and histopathology) in all rectal cancer patients will
lead to improvement of rectal cancer treatment and create
opportunities for feedback to the MDT.
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